Additionally, MET [32] and PI3K/AKT/mTOR pathway [33] activation are both associated with poor prognosis, and animal modeling indicates that genetic activation of these pathways in the context of NF1 loss drives MPNST growth and is targetable therapeutically [34, 35]. Here, AKT1 is linked to malignant peripheral nerve sheath tumor.